12 results about "Serum mirna" patented technology

The invention provides a patient serum miRNA expression level detection method and system, and relates to the field of biomedical detection.The method comprises the steps that on the basis of synchronously collecting multi-channel fluorescence signals, a common time-space change mode of all channels is extracted through statistical analysis, and a time-space change mode of all the channels is obtained; then systematic common mode interference signals are separated by means of adaptive filtering or curved surface fitting and the like, interference is accurately deducted for physical coordinates of each reaction channel, a real reaction process is reconstructed, then amplitude standardization and time axis nonlinear alignment are performed on a reconstruction curve, signal scales and dynamic references are unified, and the real reaction process is reconstructed. And finally extracting characteristic parameters and quantifying the expression level of the target miRNA with high precision in combination with a standard curve model. The problems of reaction kinetics heterogeneity caused by a serum matrix effect and difficulty in stripping systematic noise caused by instrument drifting are solved at the same time, and the accuracy, the reliability and the repeatability of multi-sample parallel detection are greatly improved.

The present invention discloses a miRNA marker combination, a kit and an application for distinguishing central nervous system lymphoma and glioblastoma in the fields of biomedicine and molecular biology. The miRNA marker combination includes one or more combinations of the following miRNAs detectable in human serum: miR-371a-3p, miR-3202, miR-6757-3p, miR-4763-3p, miR-1915-3p, and miR-3679-5. The present invention uses bioinformatics and molecular biology techniques to perform differential analysis based on blood miRNA chip detection data of PCNSL and GBM in the NCBI-GEO database, establishes candidate serum miRNA markers for PCNSL and GBM, and constructs a risk assessment model, thereby improving detection efficiency and accuracy, reducing the probability of misdiagnosis, and improving patient prognosis.

The invention relates to an S12micro model for cancer auxiliary diagnosis and prognosis evaluation and application of the S12micro model. According to the method, miRNA expression profiles of more than 20000 cases of samples of 8 common data sets are analyzed, 113 combinations of 12 machine learning algorithms are adopted for modeling and verification, 12 key miRNAs are screened out, and an S12micro model is constructed. The average AUC of the model in a large-scale verification queue is up to 0.987 and is obviously superior to that of the existing 42 serum miRNA marker combinations, and the excellent performance of the serum miRNA marker combination is further verified through clinical samples. The S12micro model is based on a serum sample, does not need invasive operation, has the detection cost lower than that of imaging examination, has the advantages of high sensitivity, high specificity and noninvasiveness, is suitable for early screening and auxiliary diagnosis of various cancers, is higher in universality, can effectively fill the blank of accurate diagnosis and prognosis evaluation of the cancers, and has a wide application prospect. And the method has important practical significance, and has extremely high social value and market application prospect.

The invention belongs to the technical field of miRNA detection, and particularly relates to a biosensor for detecting miRNA, the biosensor comprises a transcription-coupled positive feedback CRISPR / Cas13a system and an electrochemical luminescence hydrogel, the electrochemical luminescence hydrogel is aminocarbazole-sodium alginate-polyethylene glycol hydrogel with the surface modified with gold nanoparticles, and the gold nanoparticles are added to the aminocarbazole-sodium alginate-polyethylene glycol hydrogel. The construction method of the biosensor comprises the following steps: polishing the surface of a glassy carbon electrode on chamois by using aluminum oxide powder, coating the treated surface of the glassy carbon electrode with aminocarbazole-sodium alginate-polyethylene glycol hydrogel with the surface modified with gold nanoparticles, then drying to form a modified film, mixing tris (2-carboxyethyl) phosphine with S1, incubating, and drying to obtain the biosensor with the gold nanoparticle modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole-sodium alginate-polyethylene glycol modified amino carbazole. Dropwise adding to the surface of the glassy carbon electrode modified by the hydrogel; the preparation method comprises the following steps: firstly preparing a glassy carbon electrode, then using mercaptohexanol to seal, then capturing pre-prepared DA-S2, reacting and constructing to form an S1-DA-S2 structure, then dropwise adding a transcriptional coupled positive feedback CRISPR / Cas13a system reaction mixed solution to the surface of the glassy carbon electrode, and incubating, so that simple and rapid serum miRNA recognition and nucleic acid signal amplification can be realized. The invention provides a brand new design concept and technical approach for constructing a novel efficient and stable miRNA detection method, and is expected to meet the clinical requirements on high-sensitivity miRNAs detection.

The application discloses a kind of biological sensors for detecting serum miRNA-21 of cervical cancer patient, it is related to the technical field of biosensor.The biological sensor of the application utilizes the large specific surface area of UiO-66-NH2, and Ru (bpy) 3 2+ Molecule (energy donor) and Ag nanoparticle (energy acceptor) are assembled in the same UiO-66-NH2, so that it exhibits high-efficiency intramolecular RET-ECL effect, enhances the ECL sensing response; Based on the stand point mediated strand displacement reaction and catalytic hairpin self-assembly signal amplification strategy, the diversity of substrate selection and the sensitivity of detection are improved; The catalysis of biological enzyme is used to improve the accuracy and timeliness of the biosensor. The biosensor of the application can be applied to the sensitive determination of miRNA-21 in the serum of cervical cancer patients, and has important application value.

The invention discloses a biosensor for detecting serum miRNA-21 of a cervical cancer patient, and relates to the technical field of biosensors. According to the biosensor disclosed by the invention, the Ru (bpy) 3 < 2 + > molecules (energy donors) and the Ag nanoparticles (energy receptors) are assembled in the same UiO-66-NH2 by utilizing the relatively large specific surface area of the UiO-66-NH2, so that the biosensor shows an efficient intramolecular RET-ECL effect, and the ECL sensing response is enhanced; based on a foothold mediated strand displacement reaction and a catalytic hairpin self-assembly signal amplification strategy, the diversity of substrate selection and the sensitivity of detection are improved; the accuracy and timeliness of the biosensor are improved by utilizing catalysis of the biological enzyme. The biosensor provided by the invention can be applied to sensitive determination of miRNA-21 in serum of cervical cancer patients, and has important application value.

This invention relates to the field of biotechnology, specifically the application of miR-541 in the preparation of a non-invasive diagnostic and prognostic assessment kit for liver fibrosis / cirrhosis. This invention utilizes serum miRNA extraction, reverse transcription, and RT-PCR to determine the expression level of miR-541 in the serum of cirrhotic patients. Combined with follow-up information, it confirms a correlation between miR-541 expression and the prognosis of cirrhotic patients. miR-541 can be used to prepare a non-invasive molecular marker for assessing the prognosis of cirrhotic patients, and it also has important guiding significance for preventing or delaying the development of decompensated cirrhosis.

The invention belongs to the technical field of medical diagnosis, and particularly relates to a method for constructing an early HCC prediction model based on machine learning and serum miRNA. A large-scale serum miRNA chip data set and an analysis process driven by machine learning are utilized, feature selection and stacking integrated modeling are combined in the process, a public serum miRNA chip data set is utilized to identify a biomarker of the early hepatocellular carcinoma, and a high-performance early hepatocellular carcinoma diagnosis model is developed. As a non-invasive tool, the model has strong clinical transformation potential in early HCC screening. Subsequently, a stem-loop reverse transcription combined quantitative polymerase chain reaction technology is used for quantifying a serum miRNA spectrum type, an optimal HCC detection model XGBoostPLRglm is developed, and the provided serum miRNA characteristic is an effective tool for improving early hepatocellular carcinoma detection and possibly contributes to improvement of prognosis evaluation of hepatocellular carcinoma.

The invention relates to a method for preparing magnetic agarose microspheres based on a hydrogel micro-fluidic system and application of the magnetic agarose microspheres in enrichment and detection of serum miRNA. The magnetic microspheres are prepared through a micro-fluidic chip, agarose with low gel degree is mixed with Fe3O4 as a dispersion phase, ultrasonic uniform mixing is performed, a dropping liquid is prepared, the dropping liquid is collected and frozen, and the magnetic agarose microspheres are obtained. And deoiling and cleaning to obtain the magnetic agarose microspheres. A large number of microspheres with uniform sizes can be rapidly and efficiently prepared through the micro-fluidic chip, and compared with commercialized magnetic beads, the experiment cost is greatly saved; compared with a traditional magnetic agarose microsphere preparation method, the microfluidic method is faster, more efficient and free of pollution, and the prepared microspheres are more attractive. Due to the natural porous structure of agarose, various functional molecules can be coupled, various small biological molecules can be enriched and rapidly separated through magnetic adsorption, and wide application prospects are achieved in the aspects of biological detection, clinical medicine and the like.

This invention provides a method and system for detecting serum miRNA expression levels in patients, relating to the field of biomedical detection. The method includes: simultaneously acquiring multi-channel fluorescence signals; firstly, extracting common temporal-spatial variation patterns across channels through statistical analysis; then, separating systematic common pattern interference signals using adaptive filtering or surface fitting techniques; and precisely subtracting this interference from the physical coordinates of each reaction channel to reconstruct the true reaction process. Subsequently, the reconstructed curves are normalized in amplitude and nonlinearly aligned with the time axis to unify the signal scale and kinetic benchmark. Finally, feature parameters are extracted and combined with a standard curve model to quantify the target miRNA expression level with high precision. This invention simultaneously solves the problems of reaction kinetic heterogeneity caused by serum matrix effects and the difficulty in removing systematic noise caused by instrument drift, significantly improving the accuracy, reliability, and repeatability of multi-sample parallel detection.

The application discloses application of hsa-miR-144-5p as a postmenopausal osteoporosis diagnosis marker. The application adopts high-throughput gene chip technology to detect serum miRNA expression profiles of PMOP patients, and compares with postmenopausal non-osteoporosis population, screens differential expression miRNAs between the two, further verifies the differential level of the selected miRNA between the PMOP patients and n-PMOP through real-time fluorescent quantitative PCR technology, confirms the clinical application value of the screened marker, and finally provides a simple and easy, high-precision biomarker for clinical PMOP diagnosis.

This invention discloses an internal reference gene for the standardization of serum miRNAs in liver cancer and its application. The provided internal reference gene for the standardization of serum miRNAs in liver cancer is selected from any one of three microRNAs, miR-8066, miR-12115, and miR-423-5p, or any combination thereof. It also provides a liver cancer detection kit, including detection reagents or biochips for the specific detection of liver cancer-related target miRNAs and the internal reference gene. Furthermore, it provides a method for the standardized quantification of serum miRNAs in liver cancer, as well as a method for screening standardized internal reference genes for serum miRNAs in liver cancer. This invention provides a reliable standardized tool for the molecular diagnosis and prognostic assessment of liver cancer.